Anti-CD47 monoclonal antibody that blocks the CD47–SIRPα 'don't-eat-me' signal to enhance macrophage-mediated phagocytosis.
Humanized anti-CD47 monoclonal antibody that blocks the CD47–SIRPalpha 'don't-eat-me' checkpoint, enabling macrophage-mediated phagocytosis of tumor cells and promoting downstream anti-tumor T-cell responses.
Anti-CD47 antibody blocks the CD47–SIRPα ‘don’t‑eat‑me’ signal and opsonizes CD47+ cells; macrophages engage the Fc region via Fcγ receptors and perform antibody-dependent cellular phagocytosis, killing the target cells (with secondary T-cell responses).
Anti-CD20 chimeric monoclonal antibody that depletes B cells via complement-dependent cytotoxicity, antibody-dependent cellular cytotoxicity, and apoptosis.
Chimeric anti-CD20 monoclonal antibody that depletes CD20-positive B cells via complement-dependent cytotoxicity, antibody-dependent cellular cytotoxicity, and induction of apoptosis.
Binds CD20 on B cells, triggering complement-dependent cytotoxicity and Fc-mediated ADCC (e.g., NK cells/macrophages), and can also induce apoptosis.
An antibody-drug conjugate (ADC) targeting B7-H4 (VTCN1) on tumor cells; after binding, it is internalized and releases a cytotoxic payload to kill B7-H4-expressing cancer cells.
Monoclonal antibody targets B7-H4 (VTCN1) on tumor cells; upon binding and internalization, it releases an attached cytotoxic payload inside the cell, leading to apoptosis of B7-H4–expressing cancer cells.
The ADC binds B7-H4 on target cells, is internalized, and releases a cytotoxic payload intracellularly, inducing apoptosis of B7-H4–expressing cells.
Autologous anti-CD19 chimeric antigen receptor (CAR) T-cell therapy redirecting cytotoxic T cells to CD19-expressing B cells.
Autologous T cells engineered with an anti‑CD19 chimeric antigen receptor containing CD28 costimulatory and CD3ζ signaling domains; upon infusion, CAR T cells bind CD19 on B cells, become activated, proliferate, release cytokines, and mediate cytotoxic killing of CD19‑expressing malignant B cells.
Anti-CD19 CAR-T cells bind CD19 on B cells and, upon activation via CD28/CD3ζ, induce cytolytic killing through perforin/granzyme-mediated apoptosis and cytokine release.
Autologous anti-CD19 CAR T-cell therapy that targets CD19 on malignant B cells to mediate T-cell cytotoxicity.
Autologous T cells engineered to express an anti‑CD19 chimeric antigen receptor with a 4‑1BB (CD137) costimulatory domain and CD3‑zeta signaling. Upon binding CD19 on malignant B cells, the CAR triggers T‑cell activation, proliferation, cytokine release, and perforin/granzyme‑mediated cytotoxic killing of CD19‑positive tumor cells.
Anti-CD19 CAR T cells bind CD19 and, upon activation, kill CD19+ cells via perforin/granzyme-mediated cytolysis (and death receptor signaling).